# A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

> **NCT02877264** · PHASE1 · COMPLETED · sponsor: **Aviragen Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** vapendavir 132 mg capsule
- **DRUG:** vapendavir 264 mg tablet
- **DRUG:** vapendavir 24 mg/mL oral suspension

## Key facts

- **NCT ID:** NCT02877264
- **Lead sponsor:** Aviragen Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-08
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877264, "A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02877264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*